more

Cerner Corporation (CERN)

(Delayed Data from NSDQ)

$68.47 USD

+0.46 (0.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $68.46 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in North Kansas City, MO, Cerner Corporation (CERN) provides healthcare information technology (HCIT) solutions worldwide. The company offers software and hardware solutions that give healthcare providers secure access to clinical, administrative and financial data in a short time. As of February 2018, its products were in use at more than 27,000 facilities around the world. The company had more than 28,000 employees globally, with over 13,000 in Kansas City, Missouri. More than 28,000 Cerner associates are currently employed in 26 countries worldwide

Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research Published on April 29,2020

Cerner (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Professional and Managed services units, and international revenue growth.

Cerner (CERN) Surpasses Q1 Earnings Estimates

by Zacks Equity Research Published on April 28,2020

Cerner (CERN) delivered earnings and revenue surprises of 5.97% and -1.20%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

CERNPositive Net Change

Cerner (CERN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research Published on April 23,2020

Cerner's (CERN) first-quarter results are likely to reflect solid show by Population Health, Revenue Cycle and IT Works.

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research Published on April 20,2020

Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, margin contraction remains a woe.

medical

Here's Why You Should Retain Cerner (CERN) Stock for Now

by Zacks Equity Research Published on March 18,2020

Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margin remains a woe.

medical

Cerner (CERN) Down 6.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research Published on March 05,2020

Cerner (CERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CERNPositive Net Change

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research Published on February 18,2020

Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.

medical

Cerner (CERN) Catches Eye: Stock Jumps 5.9%

by Zacks Equity Research Published on February 06,2020

Cerner (CERN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

CERNPositive Net Change

medical

Cerner (CERN) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research Published on February 05,2020

Cerner (CERN) fourth-quarter results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.

Cerner (CERN) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research Published on February 04,2020

Cerner (CERN) delivered earnings and revenue surprises of 1.35% and 0.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

CERNPositive Net Change

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

by Zacks Equity Research Published on February 04,2020

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

medical

Here's Why You Should Hold on to OPKO Health Stock for Now

by Zacks Equity Research Published on February 03,2020

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

medical

Cerner (CERN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on January 30,2020

Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.

Varian (VAR) Earnings and Revenues Miss Estimates in Q1

by Zacks Equity Research Published on January 30,2020

Varian (VAR) gains from core Oncology segment in fiscal Q1.

Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall

by Zacks Equity Research Published on January 29,2020

Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.

Cerner (CERN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research Published on January 28,2020

Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.